Research progress of potential anti-tumor and anti-inflammatory target PARP14 / 中国药理学通报

PARP14 is an intracellular single AI)P-ribose transferase member of the superfamily of polyADP-ribose polymerases.PARP14 is associated with a wide range of biochemical transfor-mations in vivo through poly( ADP-ribosylation, PAKs) modifi- cation of target proteins.For example, it plays an important part in eellular transcriptional regulation, stress response, DNA re-pair, RNA splieing, mitoehondrial function, division, and nu- cleosome formation.PAR PI 4 is elosely related to the development and progression of cancers (such as hepatoeellular carcino- ma, multiple myeloma and pancreatic cancer) , metabolie diseases, and inflammatory diseases, making it a potential dnig dis- eovery target.This research reviews the structure and biological functions of PARP14, and summarizes the role of PARP14 in disease, as well as the existing PARP14 small molecule inhibitors and decompressors.It provides a brief update to the research and development of PARP14 inhibitors and decompressors to assist in the development of selective PARP14 inhibitors and decompressors.It provides reference for the research and development of drugs or chemical sensitizers targeting PARP14.

Evaluation on Efficacy and Safety of Jinying Capsule in Treatment of Pelvic Inflammatory Disease Patients with Accumulated Damp-heat Syndrome / 中国中西医结合杂志

<p><b>OBJECTIVE</b>To evaluate the efficacy and safety of Jinying Capsule (JC) in treating pelvic inflammatory disease patients with accumulated damp-heat syndrome (ADHS).</p><p><b>METHODS</b>Totally 328 patients were recruited in a prospective, positive drug parallel controlled, and multi-center clinical trial. Of them 213 patients in the treatment group took JC (0.5 g per capsule), 4 capsules each time, 3 times per day, while 115 patients in the control group took Kangfuyan Capsule (KC, 0.4 g per capsule), 3 capsules each time, twice per day. The course of treatment was 4 weeks for all. Scores of Chinese medical syndromes, visual analogue scale (VAS) of the lower abdominal pain, and European quality of life-five dimension scale (EQ-5D) were observed before treatment and after 4 weeks of treatment.</p><p><b>RESULTS</b>There were 204 patients in the treatment group and 109 in the control group who completed this trial. The total effective rate of Chinese medical syndrome was 89.71% (183/204 cases) in the treatment group and 76.15% (83/109 cases) in the control group (P < 0.01). Compared with before treatment in the same group, EQ-5D scores increased, and VAS scores of the lower abdominal pain decreased in the two groups after treatment. EQ-5D scores was 0.857 ± 0.157 in the treatment group, obviously higher than that in the control group (0.753 ± 0.126, P < 0.05). VAS scores of the lower abdominal pain was 2.14 ± 1.23 in the treatment group, lower than that in the control group (2.33 ± 1.24), but with no statistical difference between the two groups (P > 0.05). No adverse reaction occurred in the two groups.</p><p><b>CONCLUSION</b>JC was superior to KC in improving Chinese medical syndrome and quality of life of pelvic inflammatory disease patients with accumulated damp-heat syndrome.</p>